Skip to Content

Zegalogue (dasiglucagon) Disease Interactions

There are 3 disease interactions with Zegalogue (dasiglucagon):

Major

Glucagon (Includes Zegalogue) insulinoma

Major Potential Hazard, Moderate plausibility. Applies to: Insulinoma

The use of glucagon is contraindicated in patients with insulinoma or glucagonoma as it may cause secondary hypoglycemia. Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor for changes in blood glucose levels during treatment. If a patient develops symptoms of hypoglycemia after a dose of glucagon, administer glucose orally or intravenously.

References

  1. "Product Information. Glucagon (glucagon)." Lilly, Eli and Company, Indianapolis, IN.
Major

Glucagon (Includes Zegalogue) pheochromocytoma

Major Potential Hazard, Moderate plausibility. Applies to: Pheochromocytoma

The use of glucagon is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor, which may result in a sudden and marked increase in blood pressure.

References

  1. "Product Information. Glucagon (glucagon)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Glucagon (Includes Zegalogue) glycogen depletion

Moderate Potential Hazard, Moderate plausibility. Applies to: Adrenal Insufficiency, Malnourished, Panhypopituitarism

Glucagon reverses hypoglycemia via mobilization of hepatic glycogen. It is not useful for treating hypoglycemic patients who are glycogen-depleted, a condition that can occur in starvation, adrenal insufficiency, or chronic hypoglycemia. Glucose administration should be considered in such cases.

References

  1. "Product Information. Glucagon (glucagon)." Lilly, Eli and Company, Indianapolis, IN.

Zegalogue (dasiglucagon) drug interactions

There are 23 drug interactions with Zegalogue (dasiglucagon)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.